摘要
目的探讨阿莫西林克拉维酸钾干混悬剂联合异丙托溴铵雾化吸入治疗支气管哮喘患儿合并肺部感染的临床效果。方法选取2014年8月-2016年8月医院收治的支气管哮喘合并肺部感染患儿120例为研究对象,随机分为试验组和对照组,各60例。对照组患儿采取异丙托溴铵雾化吸入治疗,试验组在对照组的基础上加用阿莫西林克拉维酸钾干混悬剂(7∶1)口服治疗;治疗后对两组患儿的治疗效果进行判定;观察记录两组患儿发烧改善、咳嗽改善、肺部啰音消失和肺部阴影消失的时间;采用酶联免疫吸附法(ELISA)测定治疗前后两组患儿肿瘤坏死因子-α(TNF-α)、白细胞介素-4(IL-4)和IL-6的水平;记录两组患儿治疗期间不良反应发生情况;随访6个月,记录两组患儿支气管哮喘复发情况。结果试验组患儿疗效优于对照组(P<0.001);治疗后,试验组患儿发烧消失、咳嗽改善、肺部啰音改善及肺部阴影消失时间分别为(2.18±0.57)天、(4.95±1.08)天、(5.87±1.67)及(6.27±1.84)天均少于对照组(P均<0.001);试验组患儿血清中IL-6、TNF-α和IL-4的浓度分别为(2.08±0.37)μg/L,(2.41±0.57)μg/L及(86.79±14.22)ng/L均低于对照组(P均<0.001);随访期间,试验组患儿支气管哮喘复发2例少于对照组10例(P=0.029);治疗期间,试验组患儿未出现不良反应,对照组1例患儿出现胃肠不适。结论阿莫西林克拉维酸钾干混悬剂联合异丙托溴铵雾化吸入治疗小儿支气管哮喘合并肺部感染疗效较好,安全性较高。
OBJECTIVE To investigate the clinical effect of amoxicillin clavulanate potassium dry suspension combined with ipratropium bromide inhalation therapy for bronchial asthma complicated with pulmonary infections.METHODS From Aug.2014 to Aug.2016,120 children with bronchial asthma complicated with pulmonary infection were enrolled in this study.The patients were divided into treatment group and control group according to the random number table method,with 60 cases in each group.In the control group,children were treated with ipratropium bromide inhalation therapy,and in treatment group,children were treated with amoxicillin clavulanate potassium dry suspension（7∶1）oral treatment on the base of control group.After treatment,the treatment effect of the two groups of children was recorded.The time of disappearance of fever,cough,lung rales and lung shadow of the two groups were observed and recorded.The levels of serum inflammatory factors（TNF-α,IL-4 and IL-6）in the two groups were measured by enzyme-linked immunosorbent assay（ELISA）.The incidence of adverse events during the treatment of the two groups was recorded.And 6 months after the end of treatment,the recurrence of bronchial asthma was recorded.RESULTS The treatment group had significantly better curative effect than the control group（P〈0.001）.The disappearance of fever,the improvement of cough,the improvement of pulmonary rales and the disappearance of lung shadow in the treatment group were（2.18±0.57）days,（4.95 ± 1.08）days,（5.87±1.67）days and（6.27±1.84）days,respectively,which were all significantly shorter than those in the control group（all P〈0.05）.After treatment,the concentrations of TNF-α,IL-4 and IL-6 in the treatment group were（2.08±0.37）μg/L,（2.41±0.57）μg/L and（86.79±14.22）ng/L,which were significantly lower than those in the control group（all P〈0.001）.During the follow-up period,the bronchial asthma recurred in 2 cases in the treatment group,which was less than 10 cases in the cont
作者
张特
罗小春
王斌
於建平
张双美
ZHANG Te;LUO Xiao-chun;WANG Bin;YU Jian-ping;ZHANG Shuang-mei(Huzhou Central Hospital, Huzhou, Zhejiang 313000, China)
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2018年第11期1654-1657,共4页
Chinese Journal of Nosocomiology
基金
浙江省医药卫生科技计划基金资助项目(2015DTA016)
关键词
支气管哮喘
肺部感染
阿莫西林克拉维酸钾干混悬剂
异丙托溴铵
Bronchial asthma
Pulmonary infection
Amoxicillin clavulanate potassium dry suspension
Ipratropium bromide
